Showing results (91-100 of 208) with videos related to
Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|September 28, 2022
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastasesCaroline Dutriaux, Caroline Robert, Jean-Jacques Grob, et al.European Journal of Cancer (Oxford, England : 1990)|July 9, 2021
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenibPhilippe Saiag, Caroline Robert, Jean-Jacques Grob, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 25, 2007
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patientsNadege Bercovici, Nacilla Haicheur, Severine Massicard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsDirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 PatientsFlorian Herms, Jerome Lambert, Jean-Jacques Grob, et al.Journal of Translational Medicine|June 26, 2017
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM studyLuis de la Cruz-Merino, Lorenza Di Guardo, Jean-Jacques Grob, et al.The Lancet. Oncology|February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyMahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.Cancers|July 3, 2020
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with CrossoverCeleste Lebbé, Caroline Dutriaux, Thierry Lesimple, et al.Melanoma Research|November 11, 2024
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohortCamille Macaire, Wendy Lefevre, Sophie Dalac, et al.European Journal of Cancer (Oxford, England : 1990)|December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.Pageof 21